cgmp fda No Further a Mystery
No. 21 CFR 211.113(a) involves suitable written procedures for being established and adopted throughout manufacturing to avoid objectionable microorganisms in drug products and solutions not necessary to be sterile. Additionally, the next paragraph of USP Common Chapter Antimicrobial Effectiveness Screening reads: Antimicrobial preservativ